2020 American Transplant Congress
Longer-Term Outcomes from the THINKER and EXPANDER Trials of Transplantation Using HCV-Viremic Kidneys
*Purpose: The practice of transplanting HCV-viremic kidneys into HCV-negative recipients has become more common, but longer-term outcomes have not been reported. We present data on…2020 American Transplant Congress
Access to Direct Acting Antiviral Therapy for Recipients of Solid Organs from Hepatitis C Viremic Donors
Vanderbilt University Medical Center, Nashville, TN
*Purpose: Emerging data supports transplantation of organs from hepatitis C-positive (HCV) donors to expand the donor pool, but access to direct acting antivirals (DAAs) to…2020 American Transplant Congress
Pharmacy Led Initiatives for Treatment of Transplant Recipients of Hepatitis C Viremic Donors in a High Volume Transplant Center
Duke University Medical Center, Durham, NC
*Purpose: We describe a multidisciplinary workflow for initiation of hepatitis C virus (HCV) direct-acting antiviral (DAA) therapies post-transplant in the outpatient setting of a high…2020 American Transplant Congress
Use of Direct Acting Antiviral Medications in Transplant Recipients Receiving Organs from Hepatitis C Viremic Donors
*Purpose: The availability and high efficacy of direct acting antivirals (DAAs) to treat hepatitis C (HCV) is changing practice in solid organ transplant. A large…2020 American Transplant Congress
Use of Letermovir for Cytomegalovirus Management in Thoracic Organ Transplantation
Duke University Medical Center, Durham, NC
*Purpose: Cytomegalovirus (CMV) commonly affects thoracic solid organ transplant (SOT) recipients, and standard antiviral therapies are limited by myelosuppression, renal dysfunction, and emergence of resistance.…2020 American Transplant Congress
Experience with a BKV-Specific, Neutralizing Monoclonal Antibody (MAU868) for Treatment of Severe BK Virus Nephropathy (BKVN) after Kidney Transplant (FDA EIND #139112)
*Purpose: BK viral reactivation leading to nephropathy and allograft loss in kidney transplant recipients remains a significant challenge. No effective BKV-therapies are currently available. Management…2020 American Transplant Congress
Letermovir Treatment for Established Cytomegalovirus Infection in Transplant Recipients
*Purpose: The purpose of the study was to describe the patterns of use and clinical/virologic outcomes of letermovir treatment for established CMV infection in transplant…2020 American Transplant Congress
The Effect of Undernutrition and Immunosuppression on Cytomegalovirus Specific T Cell Responses
1Pediatrics, Duke University, Durham, NC, 2Surgery, Duke University, Durham, NC
*Purpose: Cytomegalovirus (CMV) infection remains a significant issue in transplantation, especially in those who are undernourished. While undernutrition is associated with impaired T cell immunity…2020 American Transplant Congress
Clinical and Laboratory Characteristics of Early and Late-Onset Cytomegalovirus Infection Following Universal Prophylaxis in Kidney Transplant Recipients
University of California, San Francisco, San Francisco, CA
*Purpose: Cytomegalovirus (CMV) is the most important viral infection in organ recipients and can cause life-threatening infections, compromising long-term graft function. Most transplant centers use…2020 American Transplant Congress
An OPO’s Experience in Increasing Transplantation with the Hope Project
*Purpose: The purpose of this report is to describe one OPO’s experience in participating in the Hope Project. This research project is designed to evaluate…
- « Previous Page
- 1
- …
- 3
- 4
- 5
- 6
- 7
- …
- 14
- Next Page »